• Privacy Policy
  • Terms and Conditions
  • Contact
Wednesday, June 18, 2025
Pharma Info Nepal
  • Home
  • Vacancy
  • Courses
  • License
  • Loksewa
  • Questions
  • Downloads
  • Pharmacy Books
    • Pharmacy Act and Guidelines
    • Study Materials
  • Pharmacy Notes
    • B Pharmacy
    • D Pharmacy
No Result
View All Result
  • Home
  • Vacancy
  • Courses
  • License
  • Loksewa
  • Questions
  • Downloads
  • Pharmacy Books
    • Pharmacy Act and Guidelines
    • Study Materials
  • Pharmacy Notes
    • B Pharmacy
    • D Pharmacy
No Result
View All Result
Pharma Info Nepal
No Result
View All Result
Home Notice

Aspartame Possibly Carcinogenic to Humans

Aspartame Possibly Carcinogenic to Humans

Pharma Info Nepal by Pharma Info Nepal
July 21, 2023
in Notice, Updates
0
Aspartame Possibly Carcinogenic to Humans
255
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

Aspartame Possibly Carcinogenic to Humans

Aspartame is an artificial (chemical) sweetener widely used in various food and beverage products since the 1980s, including diet drinks, chewing gum, gelatin, ice cream, dairy products such as yogurt, breakfast cereal, toothpaste and medications such as cough drops and chewable vitamins.

Assessments of the health impacts of the non-sugar sweetener aspartame are released by the International Agency for Research on Cancer (IARC) and the World Health Organization (WHO) and the Food and Agriculture Organization (FAO) Joint Expert Committee on Food Additives (JECFA). Citing “limited evidence” for carcinogenicity in humans, IARC classified aspartame as possibly carcinogenic to humans (IARC Group 2B) and JECFA reaffirmed the acceptable daily intake of 40 mg/kg body weight.

“Cancer is one of the leading causes of death globally. Every year, 1 in 6 people die from cancer. Science is continuously expanding to assess the possible initiating or facilitating factors of cancer, in the hope of reducing these numbers and the human toll,” said Dr Francesco Branca, Director of the Department of Nutrition and Food Safety, WHO. “The assessments of aspartame have indicated that, while safety is not a major concern at the doses which are commonly used, potential effects have been described that need to be investigated by more and better studies.”

The two bodies conducted independent but complementary reviews to assess the potential carcinogenic hazard and other health risks associated with aspartame consumption. This was the first time that IARC has evaluated aspartame and the third time for JECFA.

After reviewing the available scientific literature, both evaluations noted limitations in the available evidence for cancer (and other health effects).

IARC classified aspartame as possibly carcinogenic to humans (Group 2B) on the basis of limited evidence for cancer in humans (specifically, for hepatocellular carcinoma, which is a type of liver cancer). There was also limited evidence for cancer in experimental animals and limited evidence related to the possible mechanisms for causing cancer.

JECFA concluded that the data evaluated indicated no sufficient reason to change the previously established acceptable daily intake (ADI) of 0–40 mg/kg body weight for aspartame. The committee therefore reaffirmed that it is safe for a person to consume within this limit per day. For example, with a can of diet soft drink containing 200 or 300 mg of aspartame, an adult weighing 70kg would need to consume more than 9–14 cans per day to exceed the acceptable daily intake, assuming no other intake from other food sources.

IARC’s hazard identifications are the first fundamental step to understand the carcinogenicity of an agent by identifying its specific properties and its potential to cause harm, i.e. cancer. IARC classifications reflect the strength of scientific evidence as to whether an agent can cause cancer in humans, but they do not reflect the risk of developing cancer at a given exposure level. The IARC hazard evaluation considers all types of exposures (e.g. dietary, occupational). The strength-of-evidence classification in Group 2B is the third highest level out of 4 levels, and it is generally used either when there is limited, but not convincing, evidence for cancer in humans or convincing evidence for cancer in experimental animals, but not both.

“The findings of limited evidence of carcinogenicity in humans and animals, and of limited mechanistic evidence on how carcinogenicity may occur, underscore the need for more research to refine our understanding on whether consumption of aspartame poses a carcinogenic hazard,” said Dr Mary Schubauer-Berigan of the IARC Monographs programme.

JECFA’s risk assessments determine the probability of a specific type of harm, i.e. cancer, to occur under certain conditions and levels of exposure. It is not unusual for JECFA to factor IARC classifications into its deliberations.

“JECFA also considered the evidence on cancer risk, in animal and human studies, and concluded that the evidence of an association between aspartame consumption and cancer in humans is not convincing,” said Dr Moez Sanaa, WHO’s Head of the Standards and Scientific Advice on Food and Nutrition Unit. “We need better studies with longer follow-up and repeated dietary questionnaires in existing cohorts. We need randomized controlled trials, including studies of mechanistic pathways relevant to insulin regulation, metabolic syndrome and diabetes, particularly as related to carcinogenicity.”

The IARC and JECFA evaluations of the impact of aspartame were based on scientific data collected from a range of sources, including peer-reviewed papers, governmental reports and studies conducted for regulatory purposes. The studies have been reviewed by independent experts, and both committees have taken steps to ensure the independence and reliability of their evaluations.

IARC and WHO will continue to monitor new evidence and encourage independent research groups to develop further studies on the potential association between aspartame exposure and consumer health effects.

Source: https://www.who.int/news/item/14-07-2023-aspartame-hazard-and-risk-assessment-results-released



  • List of WHO GMP Certified Pharmaceutical Industry in Nepal
  • WHO Alert on 4 Indian Cough Syrups as 66 Gambian Kids Die
  • WHO Model List of Essential Medicines 22nd List (2021)

 

Tags: AspartameCarcinogenicMedicine Information
Previous Post

Difference Between New ORS and Old ORS

Next Post

List of Diploma Pharmacy Colleges in Nepal

Pharma Info Nepal

Pharma Info Nepal

Pharma Info Nepal: Nepal's No. 1 Pharmacy Blog Pharma Info Nepal is a trusted and leading platform dedicated to empowering pharmacy professionals across Nepal. Since its inception, the platform has been committed to sharing verified job vacancies, high quality educational resources, and career-building opportunities specifically tailored for pharmacy students, pharmacists, and healthcare professionals. Thousands of individuals from the pharmacy field rely on Pharma Info Nepal as their go to source for critical updates and resources. Whether you're preparing for the Nepal Pharmacy Council license exam or Loksewa examinations, seeking national and international pharmacy jobs, or exploring scholarships and fellowships, we ensure that you're equipped with the latest and most relevant information. Pharma Info Nepal also delivers regular updates on drug policies, regulatory changes from the Department of Drug Administration (DDA), Nepal Pharmacy Council (NPC), and the Ministry of Health and Population (MoHP). We further support professional development through the sharing of national guidelines, educational materials, and awareness campaigns aimed at strengthening the pharmacy profession in Nepal. Thank you for trusting Pharma Info Nepal — a platform that connects, informs, and uplifts Nepal’s pharmacy community. Together, let’s build a professionally strong, informed, and healthier future.

Related Posts

Nepal Pharmacy Council 28th Name Registration Exam Result Published (Assistant Pharmacist)
Updates

Nepal Pharmacy Council 28th Name Registration Exam Result Published (Assistant Pharmacist)

June 15, 2025
DDA Drug Recall Notice: Substandard Batches of Calcifer Drops Identified
Notice

DDA Drug Recall Notice: Substandard Batches of Calcifer Drops Identified

June 12, 2025
DDA Drug Recall Notice | Substandard Injections Recalled
Notice

DDA Drug Recall Notice | Substandard Injections Recalled

June 10, 2025
NEPAL PHARMACY COUNCIL NOTICE
Notice

Nepal Pharmacy Council Announces 28th Licensing Examination Important Notice

June 4, 2025
Best NPC License Preparation Classes in Nepal for Pharmacy Students
License

Best NPC License Preparation Classes in Nepal for Pharmacy Students

May 22, 2025
WHO-GMP Certified Domestic Drug Manufacturers in Nepal: Current Status and Future Outlook
Updates

WHO-GMP Certified Domestic Drug Manufacturers in Nepal: Current Status and Future Outlook

May 21, 2025
Load More
Next Post
List of Diploma Pharmacy Colleges in Nepal

List of Diploma Pharmacy Colleges in Nepal

Discussion about this post

Recommended

Nepal Pharmacy Council 28th Name Registration Exam Result Published (Assistant Pharmacist)

Nepal Pharmacy Council 28th Name Registration Exam Result Published (Assistant Pharmacist)

June 15, 2025
DDA Drug Recall Notice: Substandard Batches of Calcifer Drops Identified

DDA Drug Recall Notice: Substandard Batches of Calcifer Drops Identified

June 12, 2025
Vacancy Pharmacy Supervisor Loksewa Sudurpashchim Province

Pharmacy Loksewa Vacancy – Sudurpashchim Province

June 11, 2025
DDA Drug Recall Notice | Substandard Injections Recalled

DDA Drug Recall Notice | Substandard Injections Recalled

June 10, 2025
Vacancy Announcement Pharmacy Assistant at TU Teaching Hospital

Vacancy Announcement Pharmacy Assistant at TU Teaching Hospital

June 10, 2025
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Instagram

About Pharma Info Nepal

Pharma Info Nepal is a dedicated platform led by Nabin Bista, focused on empowering pharmacy students and professionals in Nepal. We provide high-quality educational resources, exam preparation materials, and professional guidance for pharmacy licensure exams and beyond. Our mission is to uplift the pharmacy profession in Nepal by fostering knowledge, skills, and excellence in pharmaceutical practice.

Explore our services, stay updated on pharmacy trends, and join a community striving for innovation and professionalism in healthcare.

Important Information

All content available on this website, including text, images, files, and other resources, is strictly protected under applicable copyright and intellectual property laws. Any reuse, reproduction, or redistribution of materials without prior written permission from Pharma Info Nepal is prohibited and may result in legal action.

Pharma Info Nepal operates as a registered company dedicated to maintaining the authenticity and integrity of its content and services.

Thank you for respecting our policies and supporting our mission to advance pharmacy education and practice.

Categories

  • B Pharmacy
  • Colleges
  • D Pharmacy
  • Downloads
  • License
  • Loksewa
  • M Pharmacy
  • Medicinal Chemistry
  • Notice
  • Nursing
  • Pharmacognosy
  • Pharmacology
  • Pharmacy Notes
  • Questions
  • Scholarship
  • Study Materials
  • Syllabus
  • Updates
  • Vacancy

DOWNLOADS

Pharmacy Book 

Pharmacy Act and Guidelines

About Pharma Info Nepal

About Admin

  • Home
  • Vacancy
  • Courses
  • License
  • Loksewa
  • Questions
  • Downloads
  • Pharmacy Books
  • Pharmacy Notes

© 2025 Pharma Info Nepal | All Rights Reserved

error:
No Result
View All Result
  • Courses
  • Questions
  • Downloads
  • About Pharma Info Nepal 

© 2025 Pharma Info Nepal | All Rights Reserved